210 related articles for article (PubMed ID: 17893004)
1. Low plasma levels of adiponectin are associated with low risk for future cardiovascular events in patients with clinical evident vascular disease.
Hajer GR; van der Graaf Y; Olijhoek JK; Edlinger M; Visseren FL
Am Heart J; 2007 Oct; 154(4):750.e1-7. PubMed ID: 17893004
[TBL] [Abstract][Full Text] [Related]
2. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study.
Becker B; Kronenberg F; Kielstein JT; Haller H; Morath C; Ritz E; Fliser D;
J Am Soc Nephrol; 2005 Apr; 16(4):1091-8. PubMed ID: 15743998
[TBL] [Abstract][Full Text] [Related]
3. Low plasma HDL-c, a vascular risk factor in high risk patients independent of LDL-c.
Hajer GR; van der Graaf Y; Bots ML; Algra A; Visseren FL;
Eur J Clin Invest; 2009 Aug; 39(8):680-8. PubMed ID: 19453647
[TBL] [Abstract][Full Text] [Related]
4. Plasma adiponectin distribution in a Mediterranean population and its association with cardiovascular risk factors and metabolic syndrome.
Salas-Salvadó J; Granada M; Bulló M; Corominas A; Casas P; Foz M
Metabolism; 2007 Nov; 56(11):1486-92. PubMed ID: 17950098
[TBL] [Abstract][Full Text] [Related]
5. Serum uric acid levels and risk for vascular diseases in patients with metabolic syndrome.
Hjortnaes J; Algra A; Olijhoek J; Huisman M; Jacobs J; van der Graaf Y; Visseren F
J Rheumatol; 2007 Sep; 34(9):1882-7. PubMed ID: 17696269
[TBL] [Abstract][Full Text] [Related]
6. The association between pulse wave velocity and metabolic syndrome and adiponectin in patients with impaired fasting glucose: cardiovascular risks and adiponectin in IFG.
Nam JS; Park JS; Cho MH; Jee SH; Lee HS; Ahn CW; Lowe WL; Kim KR
Diabetes Res Clin Pract; 2009 May; 84(2):145-51. PubMed ID: 19261346
[TBL] [Abstract][Full Text] [Related]
7. Plasma adrenomedullin as an independent predictor of future cardiovascular events in high-risk patients: comparison with C-reactive protein and adiponectin.
Nishida H; Horio T; Suzuki Y; Iwashima Y; Kamide K; Kangawa K; Kawano Y
Peptides; 2008 Apr; 29(4):599-605. PubMed ID: 18222566
[TBL] [Abstract][Full Text] [Related]
8. Effect of metabolic syndrome or type II diabetes mellitus on the occurrence of recurrent vascular events in hypertensive patients.
Vlek AL; van der Graaf Y; Spiering W; Visseren FL;
J Hum Hypertens; 2008 May; 22(5):358-65. PubMed ID: 18273039
[TBL] [Abstract][Full Text] [Related]
9. Association of plasma adiponectin and cardiovascular risk profiles in nondiabetic uremic patients on peritoneal dialysis.
Tsao YT; Hsu YJ; Chu NF; Lai CH; Chiu JS; Lin SH
J Nephrol; 2008; 21(5):744-52. PubMed ID: 18949730
[TBL] [Abstract][Full Text] [Related]
10. Metabolic syndrome and the risk of new vascular events and all-cause mortality in patients with coronary artery disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm.
Wassink AM; van der Graaf Y; Olijhoek JK; Visseren FL;
Eur Heart J; 2008 Jan; 29(2):213-23. PubMed ID: 18199567
[TBL] [Abstract][Full Text] [Related]
11. Adiponectin and insulin sensitivity in primary aldosteronism.
Fallo F; Della Mea P; Sonino N; Bertello C; Ermani M; Vettor R; Veglio F; Mulatero P
Am J Hypertens; 2007 Aug; 20(8):855-61. PubMed ID: 17679033
[TBL] [Abstract][Full Text] [Related]
12. Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk.
Blanco-Colio LM; Martín-Ventura JL; Gómez-Guerrero C; Masramon X; de Teresa E; Farsang C; Gaw A; Gensini G; Leiter LA; Langer A; Egido J
Eur J Pharmacol; 2008 May; 586(1-3):259-65. PubMed ID: 18374327
[TBL] [Abstract][Full Text] [Related]
13. Further inflammatory information on metabolic syndrome by adiponectin evaluation.
Matsushita K; Tamakoshi K; Yatsuya H; Wada K; Otsuka R; Takefuji S; Hotta Y; Kondo T; Murohara T; Toyoshima H
Int J Cardiol; 2008 Mar; 124(3):339-44. PubMed ID: 17433469
[TBL] [Abstract][Full Text] [Related]
14. High-molecular-weight adiponectin does not predict cardiovascular events in patients with type 2 diabetes.
Krzyzanowska K; Aso Y; Mittermayer F; Inukai T; Brix J; Schernthaner G
Transl Res; 2009 Apr; 153(4):199-203. PubMed ID: 19304279
[TBL] [Abstract][Full Text] [Related]
15. Circulating adiponectin: associations with risk factors and the Reynolds risk score in women without prior major cardiovascular events.
Calomfirescu N; Popa C; Jurcut R; Serban M; Ginghina C
Cardiology; 2010; 115(1):64-70. PubMed ID: 19864901
[TBL] [Abstract][Full Text] [Related]
16. Plasma adiponectin in heart transplant recipients.
Ambrosi P; Oddoze C; Nicolay A; Penet-Lorec AM; Riberi A; Métras D; Portugal H; Habib G
Clin Transplant; 2009; 23(1):83-8. PubMed ID: 19200219
[TBL] [Abstract][Full Text] [Related]
17. Serum adiponectin confers little protection against diabetes and hypertension in Turkish men.
Onat A; Hergenç G; Can G; Küçükdurmaz Z
Obesity (Silver Spring); 2009 Mar; 17(3):564-70. PubMed ID: 19238142
[TBL] [Abstract][Full Text] [Related]
18. High plasma C-reactive protein (CRP) is related to low paraoxonase-I (PON-I) activity independently of high leptin and low adiponectin in type 2 diabetes mellitus.
Dullaart RP; de Vries R; Sluiter WJ; Voorbij HA
Clin Endocrinol (Oxf); 2009 Feb; 70(2):221-6. PubMed ID: 18505467
[TBL] [Abstract][Full Text] [Related]
19. High molecular weight adiponectin as a predictor of long-term clinical outcome in patients with coronary artery disease.
Inoue T; Kotooka N; Morooka T; Komoda H; Uchida T; Aso Y; Inukai T; Okuno T; Node K
Am J Cardiol; 2007 Aug; 100(4):569-74. PubMed ID: 17697807
[TBL] [Abstract][Full Text] [Related]
20. Relation of adiponectin and high-sensitivity C-reactive protein to pulse-wave velocity and N-terminal pro-B-type natriuretic peptide in the general population.
Sung SH; Chuang SY; Sheu WH; Lee WJ; Chou P; Chen CH
Am J Cardiol; 2009 May; 103(10):1411-6. PubMed ID: 19427438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
